StockNews.AI

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

StockNews.AI • 11 hours

ORTHSNNZBH
High Materiality8/10

Information

Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% Fiscal Y...

Original source

AI Summary

SI-BONE forecasts FY 2025 revenue of $200.8-$200.9 million, 20% growth. Q4 2025 revenue expected between $56.2-$56.3 million, 15% growth. Active U.S. physicians increased by 250 to around 1,640, 18% growth. Net cash generation of ~$2 million in Q4 2025 with $147.7 million cash. Fourth quarter results are preliminary, pending final audits and adjustments.

Sentiment Rationale

The anticipated revenue and physician growth indicate strong market demand. Historical trends show that consistent revenue growth positively impacts stock prices.

Trading Thesis

Revenue reports typically influence investor sentiment quickly post-announcement.

Market-Moving

  • SI-BONE forecasts FY 2025 revenue of $200.8-$200.9 million, 20% growth.
  • Q4 2025 revenue expected between $56.2-$56.3 million, 15% growth.
  • Active U.S. physicians increased by 250 to around 1,640, 18% growth.

Key Facts

  • SI-BONE forecasts FY 2025 revenue of $200.8-$200.9 million, 20% growth.
  • Q4 2025 revenue expected between $56.2-$56.3 million, 15% growth.
  • Active U.S. physicians increased by 250 to around 1,640, 18% growth.
  • Net cash generation of ~$2 million in Q4 2025 with $147.7 million cash.
  • Fourth quarter results are preliminary, pending final audits and adjustments.

Companies Mentioned

  • ORTH (ORTH)
  • SNN (SNN)
  • ZBH (ZBH)

Corporate Developments

The reported growth in revenue and physician engagement is critical for SIBN's stock performance.

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

SANTA CLARA, Calif., January 12, 2026 (GLOBE NEWSWIRE) — SI-BONE, Inc. (NASDAQ: SIBN), a leader in developing procedural solutions for clinical challenges related to compromised bone, has reported preliminary and unaudited financial results for the fourth quarter and full year 2025. The company’s worldwide revenue is projected to be between $200.8 million and $200.9 million, marking a growth of approximately 20%.

Fourth Quarter 2025 Financial Highlights

SI-BONE's fourth quarter report reveals significant growth in various financial metrics:

  • Worldwide revenue: Estimated between $56.2 million and $56.3 million, reflecting a growth of approximately 15%.
  • U.S. revenue: Projected between $53.3 million and $53.4 million, indicating a growth of about 14%.
  • Active physicians: Nearly 1,640 active physicians in the U.S., an increase of 250 physicians, representing an 18% growth.
  • Cash and equivalents: Roughly $147.7 million, with a net cash generation of approximately $2.0 million during the quarter.

Full Year 2025 Financial Performance

For the fiscal year 2025, SI-BONE's performance reflects consistent growth:

  • Worldwide revenue: Between $200.8 million and $200.9 million, translating to around 20% growth.
  • U.S. revenue: Estimated between $190.9 million and $191.0 million, representing a growth of roughly 21%.

These figures are subject to adjustment pending the completion of financial closing procedures and audits by external auditors.

Future Outlook and Financial Results

SI-BONE plans to release its detailed financial results for the fourth quarter and full year 2025 during a call in late February 2026. Investors and analysts are encouraged to stay tuned for further updates on the company’s financial health and strategic direction.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is dedicated to advancing procedural solutions that tackle clinical bone challenges. Since its inception in 2009, the company has supported physicians in executing over 140,000 procedures. With an innovative approach to additive manufacturing, SI-BONE has established a technology platform leading in applications such as SI joint fusion, adult spinal deformity, and pelvic trauma. The efficacy of SI-BONE's technologies is backed by extensive clinical evidence, including four randomized controlled trials and over 200 peer-reviewed publications.

Investor Contact

For more information, please contact:

Saqib Iqbal
VP, FP&A, and Investor Relations
investors@SI-BONE.com

Forward-Looking Statements

This press release contains forward-looking statements regarding SI-BONE's anticipated future events and results, including expectations of continued revenue growth and financial outlook. These statements are based on current expectations and entail significant risks and uncertainties. Potential risks include adjustments to preliminary financial results during audits, challenges in product commercialization, and adverse economic conditions affecting demand for elective procedures.

Actual results may differ materially from these expectations. For comprehensive risk factors, please refer to SI-BONE’s filings with the Securities and Exchange Commission (SEC) available at www.sec.gov.

Related News